Retrospective Study
Copyright ©The Author(s) 2020.
World J Gastrointest Oncol. Aug 15, 2020; 12(8): 918-930
Published online Aug 15, 2020. doi: 10.4251/wjgo.v12.i8.918
Table 1 Comparison of baseline clinicopathological characteristics between the endoscopic mucosal resection and endoscopic submucosal dissection groups
All, n = 142EMR group, n = 87ESD group, n = 55P value
Age, yr
Median (IQR)63.5 (57-71.75)62 (57-70)66 (59-73.5)0.15
Sex, n (%)
Male79 (55.6)56 (64.4)23 (41.8)0.01
Female63 (44.4)31 (35.6)32 (58.2)
Tumor location, n (%)
Bulbs32 (22.5)17 (19.5)15 (27.3)0.31
Second portion or later110 (77.5)70 (80.5)40 (72.7)
Morphology, n (%)
Flat or depressed28 (19.7)17 (19.5)11 (20.0)1
Protruded114 (80.3)70 (80.5)44 (80.0)
Tumor size, mm
Median (IQR)8 (5.25-15)7 (5-10)15 (10.5-20)< 0.001
< 11 mm85 (59.9)71 (81.6)14 (25.5)< 0.001
≥ 11 mm57 (40.1)16 (18.4)41 (74.5)
Tumor depth, n (%)
Mucosa139 (97.9)86 (98.9)53 (96.4)0.56
Submucosa3 (2.1)1 (1.1)2 (3.6)
Histology, n (%)
Adenoma103 (72.5)72 (82.8)31 (56.4)0.001
Adenocarcinoma39 (27.5)15 (17.2)24 (43.6)
Table 2 Comparison of clinicopathological characteristics of the endoscopic mucosal resection and endoscopic submucosal dissection groups after propensity score matching
EMR group, n = 28ESD group, n = 28P valueASD
Variable matching between groups
Age, yr; ≥ 65/< 658/206/220.760.17
Sex; male/female17/1116/1210.073
Tumor location; bulbs/others8/206/220.670.17
Morphology; protruded/flat or depressed22/623/510.090
Histology; adenocarcinoma/adenoma8/207/2110.081
Tumor depth; mucosa/submucosa27/127/110
Tumor size; median (IQR)11 (6.25-15)10.5 (8-13)0.900.026
Tumor size; ≥ 11 mm/< 11 mm14/1414/1410
Table 3 Comparison of treatment outcomes between the endoscopic mucosal resection and endoscopic submucosal dissection groups after propensity score matching
EMR group, n = 28ESD group, n = 28P value
Procedure time, min
Median (IQR)6 (3-10.75)87.5 (68.5-136.5)< 0.001
En bloc resection, n (%)23 (82.1)26 (92.9)0.42
Complete resection, n (%)20 (71.4)25 (89.3)0.18
Closure of mucosal defects, n (%)24 (85.7)27 (96.4)0.35
Adverse events, n (%)1 (3.6)5 (17.9)0.19
Intraoperative perforation, n (%)0 (0)3 (10.7)0.24
Delayed perforation, n (%)0 (0)1 (3.6)1
Delayed bleeding, n (%)1 (3.6)0 (0)1
Emergency surgery, n (%)0 (0)1 (3.6)1
Hospital stay, d
Median (IQR)8 (6-10.75)11 (8.25-14.75)0.006
Follow-up duration, mo23 (11-35.5)24 (9.75-57.5)0.831
Median (IQR)
One-year follow-up, n (%)21 (75)20 (71.4)1
Local recurrence, n (%)1 (3.6)0 (0)1
Metastatic recurrence, n (%)0 (0)0 (0)-